Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Pharmacokinetics of GT20029 in Healthy Subjects
NCT06468579Phase 1Completed
- Sponsor
- Kintor Pharmaceutical Limited
- Start
- Jul 2021
- Primary completion
- Aug 2022
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of gt20029 gel placebo in acne vulgaris and androgenetic alopecia (AGA) (2 arms), sponsored by Kintor Pharmaceutical Limited. Primary endpoint: Incidence of Treatment-Emergent Adverse Events at 14 days. Started Jul 2021; status: completed.
02
Drugs
gt20029 gel placebo
03
Conditions
acne vulgarisandrogenetic alopecia (AGA)
Beyond the preview
Go deeper on NCT06468579.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06468579.